Advertisement

Topics

MyoKardia Reports Topline Results in Phase 2 Study of Mavacamten

14:31 EDT 7 Aug 2017 | Drug Discovery Development

After 12 weeks of treatment, all 10 subjects (100%) achieved a reduction in post-exercise peak LVOT gradient from a baseline mean of 125 mmHg
Contributed Author: 
MyoKardia

Original Article: MyoKardia Reports Topline Results in Phase 2 Study of Mavacamten

NEXT ARTICLE

More From BioPortfolio on "MyoKardia Reports Topline Results in Phase 2 Study of Mavacamten"

Quick Search
Advertisement